Pre-Commercial Value Assessment of a Nuclear Medicine Pair to Diagnose and Treat Neuroendocrine Tumors (NET)
When our client, a leading radiopharmaceutical company, needed support to understand the commercial opportunity represented by a Phase III radiopharmaceutical and its diagnostic radiotracer companion, Alira Health stepped in to run a comprehensive analysis.
Read on to learn how our team analyzed the market, assessed value assets, and helped our client move forward with confidence.
For more information, please contact Piergiulio Lauriano.
Subscribe to our newsletter for the latest news, events, and thought leadership